How a clinician calculates cardiovascular risk determines who gets treated — and who doesn't. A shift in the foundational equation used to estimate that risk is therefore not a technical footnote but a consequential public health decision affecting tens of millions of adults currently being evaluated for statin therapy, blood pressure management, and lifestyle interventions.
Drawing on nationally representative data from the National Health and Nutrition Examination Survey (NHANES), this analysis compares cardiovascular risk estimates generated by the longstanding 2013 Pooled Cohort Equations (PCEs) against those produced by the newer 2023 PREVENT-ASCVD equations, which underpin the 2026 dyslipidemia guidelines. The PREVENT model incorporates additional predictors — including kidney function markers and social determinants of health — not captured by the PCEs. The NHANES-based simulation reveals that the transition between these two equations produces meaningful net reclassification of individuals across risk thresholds, with a substantial portion of patients moving into lower-risk categories and a smaller cohort moving upward, altering statin eligibility for a significant share of the U.S. adult population.
From a population-health perspective, this finding carries dual implications. On one hand, downward reclassification may spare lower-risk individuals from unnecessary pharmacological intervention and its attendant side effects. On the other hand, it raises legitimate concern about under-treatment in subgroups where the PREVENT model may not yet have demonstrated sufficient predictive calibration across diverse racial and ethnic populations — a known limitation of predecessor equations as well. The NHANES dataset, while broadly representative, is cross-sectional and cannot confirm whether reclassified individuals truly experience divergent clinical outcomes. This is an important confirmatory study rather than a paradigm shift, as it quantifies in population terms what guideline committees have already signaled. The real-world clinical impact will depend heavily on physician adoption rates and how shared decision-making conversations adapt to the new thresholds.